Mr. de Ree brings over a decade of highly relevant industry experience as a former CEO at BMEYE (acquired by Edwards Lifesciences Corp.) and Dezima Pharma (acquired by Amgen Inc.). Mr. Sigger complements this profile with a financial leadership role at Nucletron and as a co-founder and current CEO at Quirem Medical which was recently acquired by Terumo Corp.
Mr. Sigger (Supervisory Board chair): “I have become impressed by the unique Sirius localization technology and the strong team behind it. Sirius Pintuition will bring a paradigm shift for both breast cancer patients and treating physicians. I look forward to supporting the full realization of this exciting technology for the benefit of patients around the world.”
The board is completed by Jan-Frens van Giessel, experienced MedTech investment partner at Holland Capital and Hubert Martens, one of the founders and former CEO of Sirius Medical who previously co-founded Sapiens Steering Brain Stimulation (acquired by Medtronic): “although I am transitioning away from the day-to-day operations of Sirius, I will continue to support the team through my Supervisory Board membership. With the deep market knowledge of Mr. Schermers, the experienced Sirius Medical team is very well positioned to make the next steps in its development under his leadership.”
“It’s a tremendous honor to work with such an experienced Supervisory Board”, says Mr. Schermers, newly appointed CEO of Sirius Medical, “we are at a critical juncture right now, having received both US and EU regulatory approvals for Sirius Pintuition, and steadily activating customers throughout the EU. The Supervisory Board will play a pivotal role in strategic decisions that enables Sirius Pintuition to become the global standard of care.”